Barr Kicks Off Enjuvia Detailing Two Years After First Approval
This article was originally published in The Pink Sheet Daily
Subsidiary Duramed will support the estrogen therapy launch with 250 sales reps.
You may also be interested in...
The agency will require additional clinical evidence pertaining to an unmet endpoint, Barr says. Two of three endpoints for the synthetic conjugated estrogens cream were met during clinical studies; the third was modified at FDA’s guidance after the trials began, the company says.
Barr plans to launch Enjuvia by early 2005 when three additional strengths of the hormone therapy product are expected to become available, the company said
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.